Explore 2026 CLL frontline choices, from all-oral acalabrutinib–venetoclax to MRD-guided care, plus pipeline advances and Richter’s strategies.
Marc J. Braunstein, MD, PhD
Advertisement
Articles by Marc J. Braunstein, MD, PhD
Experts explore the evolving landscape of chronic lymphocytic leukemia treatment, highlighting targeted therapies, MRD strategies, and future innovations.
Marc J. Braunstein, MD, PhD, discusses chimeric antigen receptor T-cell therapies, Bruton’s kinase inhibitors, and brentuximab vedotin that were highlighted at the 2020 Chemotherapy Foundation Symposium.
Marc J. Braunstein, MD, PhD, discusses the greatest challenge that still exists in the treatment paradigm of multiple myeloma.
Advertisement
Latest Updated Articles
Navigating the Future of CLL CareFebruary 4th 2026
- Choosing Wisely in CLL: A Deep Dive Into Frontline Treatment
April 15th 2026
Challenges to Overcome in Treating Multiple MyelomaDecember 4th 2019
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Alignment Reached on Phase 3 Design for RGT-61159 in ACC
2
Sofetabart Mipitecan Elicits Responses Across FRα Levels in Ovarian Cancer
3
FDA Grants Traditional Approval to Pembrolizumab in TMB-High Solid Tumors
4
FDA Grants Fast Track Status to SBE303 in Urothelial Cancer
5